Open AccessCorrelation between Aurora‐A expression and the prognosis of cervical carcinoma patients
Author(s) -
ZHANG WEI,
WANG JIAN,
LIU SHUJUAN,
HUA WEI,
XIN XIAOYAN
Publication year - 2009
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.1080/00016340902835927
Subject(s) - medicine , immunohistochemistry , carcinoma , carcinogenesis , stage (stratigraphy) , pathology , metastasis , oncology , cancer research , cancer , biology , paleontology
Objective. Aurora‐A, a novel member of the serine/threonine kinase family, has been reported to be correlated with tumorigenesis. Our aim was to investigate whether Aurora‐A expression correlates with clinicopathologic factors and prognosis of cervical carcinoma patients. Design/setting. Retrospective study. Population. Seventy‐four cervical carcinoma patients, between 1996 and 2002. Methods. Reverse transcription‐polymerase chain reaction and Western blot assays were performed to detect the expression of Aurora‐A gene in cervical carcinoma cells and paired cancerous and corresponding noncancerous tissues from 74 cervical carcinoma patients. The expression of Aurora‐A protein in tissues was also determined by immunohistochemistry. The relationships of Aurora‐A expression with clinical factors and prognosis of patients were evaluated by statistical analysis. Results. The expression of Aurora‐A mRNA and protein was significantly higher in cervical carcinoma cells than in normal cervical epithelial cell ( p <0.05). The expression of Aurora‐A mRNA in cancerous tissues was significantly higher than that in corresponding noncancerous tissues ( p <0.001). The expression of Aurora‐A protein was also increased in tumor tissues by immunochemistry. Aurora‐A transcript expression was correlated with FIGO stage ( p = 0.018), tumor differentiation ( p = 0.014), parametrial invasion ( p = 0.024), lymphnode or hematogenous metastasis ( p = 0.005 or 0.019), but not other clinicopathological factors. Patients with high Aurora‐A expression had a poorer disease‐free survival and overall survival rates than patients with low Aurora‐A expression. Multivariate analysis showed that high Aurora‐A mRNA expression was an independent prognostic factor (risk ratio: 2.88; p = 0.005). Conclusions. Aurora‐A might be used as a prognostic marker for cervical carcinoma patients.